Market Place
Sourcing Support
RECORDATI Q3 2024 Revenue +12%, EBITDA +11.8%
08 Nov 2024 //
GLOBENEWSWIRE
Recordati buys rights to rare immune drug from Sanofi for $825 mln
05 Oct 2024 //
REUTERS
Recordati records strong performance in 2024 first quarter
13 May 2024 //
THE PHARMALETTER
Italy`s Recordati sees 2023 results at top end of the range
07 Nov 2023 //
REUTERS
Recordati shares fall after core profit margin forecasts disappoint
21 Feb 2023 //
REUTERS
Recordati Announces +ve Data From PIII Linc 4 & 3; Illustrate ISTURISA Studies
15 Jun 2022 //
BUSINESSWIRE
Recordati Rare Diseases Announces Scientific Abstracts to Be Presented at Endo
08 Jun 2022 //
BUSINESSWIRE
Recordati Announces Multiple Scientific Abstracts to Be Highlighted at AACE
10 May 2022 //
BUSINESSWIRE
Recordati to Publish in The Journal of Clinical Endocrinology & Metabolism
29 Mar 2022 //
BUSINESSWIRE
Recordati acquires EUSA Pharma & its 4 rare disease drugs, but analysts question
06 Dec 2021 //
ENDPTS
Alnylam`s Givlaari receives NICE recommendation for AHP
22 Oct 2021 //
PHARMAPHORUM
Ex-Novartis, Chiasma leader joins Recordati Rare Diseases as CMO
25 Aug 2021 //
FIERCEBIOTECH
RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE
29 Jan 2021 //
GLOBENEWSWIRE
RECORDATI RARE DISEASES: CARBAGLU® 200mg Receives U.S. FDA Approval
26 Jan 2021 //
PRNEWSWIRE
Recordati: Positive Results From the PH III LINC-3 Study of Isturisa®
27 Jul 2020 //
BUSINESSWIRE
Recordati Rare Diseases Announces First European Launch of Isturisa®
02 Jun 2020 //
BUSINESSWIRE
Recordati Rare Diseases Inc. Announces Availability of ISTURISA®
26 May 2020 //
BUSINESSWIRE
Recordati Rare Diseases now holds Isturisa® European MA
08 Apr 2020 //
GLOBENEWSWIRE
RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN
26 Mar 2020 //
GLOBENEWSWIRE
Isturisa® (Osilodrostat) Approved In The U.S.
09 Mar 2020 //
PR NEWSWIRE
Still on a cash-raising spree, Takeda shops €1.5B European drug sale: report
19 Jul 2019 //
FIERCE PHARMA
Novartis offloads lagging endocrine drugs to Recordati for $390M
16 Jul 2019 //
FIERCE PHARMA
GSK preps for Pfizer consumer health JV with £1B in product sell-offs
21 Jun 2019 //
FIERCE PHARMA
Recordati to seek Canadian approval for kidney disease drug
18 Apr 2019 //
REUTERS
Recordati Ireland`s Generic Silodosin Receives Approval in Europe
23 Jan 2019 //
EMA
Recordati & Helsinn Agreement For Commercialization Rights To Ledaga®
18 Dec 2018 //
GLOBENEWSWIRE
BMS looks to sell French OTC drug unit valued at $1.8B: report
07 Jul 2018 //
FIERCE PHARMA
CVC revs up rare disease ambitions with $3.5B Recordati buy
05 Jul 2018 //
FIERCE PHARMA
CVC weighs $3B-plus Recordati buy: FT
21 Jun 2018 //
FIERCE PHARMA
EU nod for Gedeon’s novel antipsychotic Reagila
19 Jul 2017 //
PHARMA TIMES
Apricus Biosciences Announces Approval of Vitaros
18 Jan 2017 //
GLOBENEWSWIRE
Novartis in Talks to Sell Some Central Nervous System Drugs
07 Dec 2016 //
REUTERS
Recordati CEO Dies; Drug Giant Urgently Names New CEO
16 Aug 2016 //
BIOSPACE
Recordati snaps up Swiss pharma company Pro Farma
19 Jul 2016 //
PMLIVE
